MPR Weekly Dose #57 - NDA in diabetes; Post-op implant pain Tx; DEA schedules new opioid; FDA lists 200+ drugs; Rifaximin and other drugs in the pipeline news

This week we cover a new treatment submission to the FDA for the prevention of diabetes; The launch of a bupivacaine implant to treat post op pain; The DEA schedules a newly approved opioid; The FDA classifies over 200 drugs as essential and wants manufacturers to ramp up production; And more news on drugs that are in the pipeline.

Episode metadata supplied by the publisher feed · Published Nov 6, 2020

Embed this episode

Attribution link and audio player

Ready to play

MPR Weekly Dose #57 - NDA in diabetes; Post-op implant pain Tx; DEA schedules new opioid; FDA lists 200+ drugs; Rifaximin and other drugs in the pipeline news

0:00 9:22

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 9 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on November 6, 2020.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!